CD274 and non-small cell lung carcinoma: In clinical trials, the anti-TIGIT antibody tiragolumab, when combined with the anti-PD-L1 antibody atezolizumab, demonstrated an improved overall response rate (ORR) of 37.3%, compared to 20.6% with monotherapy, in patients with PD-L1-high non-small cell lung cancer (NSCLC) (51).